Xeris Biopharma Holdings, Inc.

NasdaqGS:XERS Stock Report

Market Cap: US$894.4m

Xeris Biopharma Holdings Dividends and Buybacks

Dividend criteria checks 0/6

Xeris Biopharma Holdings does not have a record of paying a dividend.

Key information

n/a

Dividend yield

0.2%

Buyback Yield

Total Shareholder Yield0.2%
Future Dividend Yieldn/a
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

Xeris Biopharma: Low Risk, Low Excitement Solid Revenue Generator

Mar 16

Investors Appear Satisfied With Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Prospects As Shares Rocket 34%

Mar 16
Investors Appear Satisfied With Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Prospects As Shares Rocket 34%

An Intrinsic Calculation For Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Suggests It's 47% Undervalued

Mar 07
An Intrinsic Calculation For Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Suggests It's 47% Undervalued

Some Shareholders Feeling Restless Over Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) P/S Ratio

Jan 30
Some Shareholders Feeling Restless Over Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) P/S Ratio

Xeris Biopharma Holdings: Promising Pipeline And Strategic Partnerships Make It Attractive

Oct 25

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Could Be Riskier Than It Looks

Sep 07
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Could Be Riskier Than It Looks

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stock Rockets 30% But Many Are Still Ignoring The Company

Jun 04
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stock Rockets 30% But Many Are Still Ignoring The Company

Xeris Biopharma: Checking-In On One Of My 'Top Ideas'

Mar 30

Analysts Are Updating Their Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Estimates After Its Full-Year Results

Mar 09
Analysts Are Updating Their Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Estimates After Its Full-Year Results

Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Shares Climb 26% But Its Business Is Yet to Catch Up

Mar 06
Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Shares Climb 26% But Its Business Is Yet to Catch Up

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Fly 32% But Investors Aren't Buying For Growth

Jan 05
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Fly 32% But Investors Aren't Buying For Growth

Xeris Pharmaceuticals Q2 2022 Earnings Preview

Aug 09

Xeris amends commercial terms for hypoglycemia therapy as partner inks buyout deal

Aug 01

Xeris Biopharma: Q1 Earnings Reveal Path To Breakeven

May 21

Xeris Continues To Execute And Build Long-Term Value Potential

Feb 22

Xeris Biopharma: Market Is Snubbing The Strongbridge Acquisition

Dec 20

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if XERS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if XERS's dividend payments have been increasing.

Dividend Yield vs Market

Xeris Biopharma Holdings Dividend Yield vs Market
How does XERS dividend yield compare to the market?
SegmentDividend Yield
Company (XERS)n/a
Market Bottom 25% (US)1.6%
Market Top 25% (US)4.7%
Industry Average (Pharmaceuticals)2.4%
Analyst forecast (XERS) (up to 3 years)n/a

Notable Dividend: Unable to evaluate XERS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate XERS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate XERS's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as XERS has not reported any payouts.

Discover strong dividend paying companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/23 06:48
End of Day Share Price 2025/03/21 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Xeris Biopharma Holdings, Inc. is covered by 11 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Chase KnickerbockerCraig-Hallum Capital Group LLC
Robin Garner KalleyCraig-Hallum Capital Group LLC
Oren LivnatH.C. Wainwright & Co.